{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T19:34:26Z","timestamp":1776627266267,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13046-015-0267-x","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T01:24:32Z","timestamp":1450833872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data"],"prefix":"10.1186","volume":"34","author":[{"name":"on behalf of the GICO group (Gruppo Italiano COlangiocarcinoma)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Caparello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna","family":"Musettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Vasile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"267_CR1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC Groen de","year":"1999","unstructured":"de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368\u201378.","journal-title":"N Engl J Med."},{"key":"267_CR2","doi-asserted-by":"crossref","unstructured":"Brandi G, Frega G, Barbera A, Palloni A. Chemotherapy in patients with advanced cholangiocarcinoma. In: Brandi G, Ercolani G, editors. Cholangiocarcinoma. Hauppauge NY, USA: Nova Science Publisher; 2015. p. 429\u201350. https:\/\/www.novapublishers.com\/catalog\/index.php?page=help .","DOI":"10.21037\/tcr.2016.08.19"},{"key":"267_CR3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sj\u00f6d\u00e9n PO, Jacobsson G, Sellstr\u00f6m H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593\u2013600.","journal-title":"Ann Oncol."},{"key":"267_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000421-200008000-00023","volume":"23","author":"CW Choi","year":"2000","unstructured":"Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425\u20138.","journal-title":"Am J Clin Oncol."},{"key":"267_CR5","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581\u20136.","journal-title":"J Clin Oncol."},{"key":"267_CR6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"267_CR7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in Japan. Br J Cancer. 2010;103:469\u201374.","journal-title":"Br J Cancer."},{"key":"267_CR8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.critrevonc.2013.05.010","volume":"88","author":"S Cereda","year":"2013","unstructured":"Cereda S, Belli C, Rognone A, Mazza E, Reni M. Second-line therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol. 2013;88:368\u201374.","journal-title":"Crit Rev Oncol Hematol."},{"key":"267_CR9","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca A, Hubner RA, Ryder WD, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25:2328\u201338.","journal-title":"Ann Oncol."},{"key":"267_CR10","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/bjc.2014.190","volume":"110","author":"L Fornaro","year":"2014","unstructured":"Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165\u20139.","journal-title":"Br J Cancer."},{"key":"267_CR11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdu379","volume":"25","author":"C Vivaldi","year":"2014","unstructured":"Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, et al. Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Ann Oncol. 2014;25:2443\u20134.","journal-title":"Ann Oncol."},{"key":"267_CR12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/sim.4200","volume":"30","author":"PC Austin","year":"2011","unstructured":"Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inference about absolute risk reduction in propensity score matched samples. Stat Med. 2011;30:1292\u2013301.","journal-title":"Stat Med."},{"key":"267_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1179\/1973947813Y.0000000133","volume":"26","author":"S He","year":"2014","unstructured":"He S, Shen J, Sun X, Liu L, Dong J. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine\/cisplatin. J Chemother. 2014;26:243\u20137.","journal-title":"J Chemother."},{"key":"267_CR14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","volume":"49","author":"J Bridgewater","year":"2013","unstructured":"Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer. 2013;49:1511.","journal-title":"Eur J Cancer."},{"key":"267_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-230X-14-143","volume":"14","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, et al. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol. 2014;14:143.","journal-title":"BMC Gastroenterol."},{"key":"267_CR16","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.29471","volume":"121","author":"B Brieau","year":"2015","unstructured":"Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Ent\u00e9rologues Oncologues. Cancer. 2015;121:3290\u20137.","journal-title":"Cancer."},{"key":"267_CR17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3748\/wjg.v21.i7.2096","volume":"21","author":"JF Guion-Dusserre","year":"2015","unstructured":"Guion-Dusserre JF, Veronique L, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015;21:2096\u2013101.","journal-title":"World J Gastroenterol"},{"key":"267_CR18","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01926236 (date last accessed: 16\/Sep\/2015)."},{"key":"267_CR19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000205388","volume":"76","author":"MS Pino","year":"2009","unstructured":"Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology. 2009;76:254\u201361.","journal-title":"Oncology."},{"key":"267_CR20","doi-asserted-by":"crossref","unstructured":"Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, et al. Capecitabine with\/without mitomycin C: results of a randomised phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. Cancer Chemother Pharmacol. 2015 [accepted for publication].","DOI":"10.1007\/s00280-015-2919-0"},{"key":"267_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1756-9966-28-62","volume":"28","author":"G Miller","year":"2009","unstructured":"Miller G, Socci ND, Dhall D, D\u2019Angelica M, DeMatteo RP, Allen PJ, et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res. 2009;28:62.","journal-title":"J Exp Clin Cancer Res."},{"key":"267_CR22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","volume":"26","author":"JS Chen","year":"2015","unstructured":"Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26:943\u20139.","journal-title":"Ann Oncol"},{"key":"267_CR23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.22212","volume":"53","author":"C Peraldo Neia","year":"2014","unstructured":"Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, et al. Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer. 2014;53:1033\u201340.","journal-title":"Genes Chromosomes Cancer."},{"key":"267_CR24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427\u201334.","journal-title":"Hepatology."},{"key":"267_CR25","doi-asserted-by":"crossref","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","volume":"10","author":"MJ Borad","year":"2014","unstructured":"Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10:e1004135.","journal-title":"PLoS Genet."},{"key":"267_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13046-014-0103-8","volume":"33","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang J, Qin C. Blockade of CXCL12\/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 2014;33:103.","journal-title":"J Exp Clin Cancer Res."},{"key":"267_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.","journal-title":"J Exp Clin Cancer Res."},{"key":"267_CR28","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963\u201371.","journal-title":"N Engl J Med."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-015-0267-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T04:28:41Z","timestamp":1599971321000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-015-0267-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/s13046-015-0267-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"156"}}